UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2023

Commission File Number: 001-39992

---

Immunocore Holdings plc

(Translation of registrant’s name into English)

 

---

92 Park Drive

Milton Park

Abingdon, Oxfordshire OX14 4RY

United Kingdom

 (Address of principal executive office)

 

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒  Form 20-F    ☐  Form 40-F

INCORPORATION BY REFERENCE

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Presentation at 41st Annual J.P. Morgan Healthcare Conference

The key highlights from the presentation include the following:

This Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company’s strategic priorities, pipeline and expansion thereof, the therapeutic potential and expected clinical benefits, of the Company’s products and product candidates, and the progress, timing, scope, expansion and results of Immunocore’s existing and planned clinical trials, including statements regarding continued global commercial expansion of KIMMTRAK, the estimated potential addressable patient population for tebentafusp for the treatment of advanced cutaneous melanoma, the timing for reporting initial data from the monotherapy and combination arms of the Phase 1/2 dose escalation trial of IMC-F106C (PRAME-A02), the Company’s belief that IMCR-R117C is the first PIWIL targeted immunotherapy, the timing for submission of an investigational new drug application for IMC-R117C, and the timing for reporting data from the single ascending dose portion of the Phase 1 clinical trial of IMC-M113V. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this Report, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. Actual results may differ materially from those expressed or implied by these forward-looking statements. For a discussion of risk factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this Report, you should refer to the Company’s filings with the U.S. SEC, including the “Risk Factors” sections contained therein. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this Report.

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---